Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | M1231 |
| Synonyms | |
| Therapy Description |
M1231 is an antibody-drug conjugate (ADC) consisting of a bispecific antibody against MUC1 and EGFR conjugated to an anti-microtubule agent, which may result in decreased proliferation of tumor cells expressing MUC1 and EGFR (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| M1231 | M-1231|M 12231 | EGFR Antibody 72 MUC1 Antibody 8 | M1231 is an antibody-drug conjugate (ADC) consisting of a bispecific antibody against MUC1 and EGFR conjugated to an anti-microtubule agent, which may result in decreased proliferation of tumor cells expressing MUC1 and EGFR (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04695847 | Phase I | M1231 | M1231 in Participants With Solid Tumors | Completed | USA | CAN | 0 |